Trial · NCT03510325
Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)
NCT03510325, Phase 3, Completed, Shanghai Mental Health Center
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT). Trials, record NCT03510325. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03510325
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Sequential Multiple-Assignment Randomized Trials to Compare Antipsychotic Treatments(SMART-CAT)
- NCT number
- NCT03510325
- Status
- Completed
- Phases
- Phase 3
- Enrollment
- 762 participants, actual
- Lead sponsor
- Shanghai Mental Health Center
- Conditions
- Schizophrenia
- Interventions
Phase 1: Olanzapine, Phase 1: Risperidone, Phase 1: Amisulpride, Phase 1: Aripiprazole, Phase 1: Perphenazine, Phase 2: Olanzapine, Phase 2: Amisulpride, Phase 2: Clozapine, Phase 3A: Clozapine extended treatment or Combined clozapine-MECT therapy, Phase 3B: Clozapine or another SGAs
- First posted
- 2018-04-27
- Last updated
- 2025-04-08
Source ClinicalTrials.gov
Registered outcomes38
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment efficacy rate | baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months | A 40% reduction or more of the total score in the Positive and Negative Syndrome Scale (PANSS). The PANSS scale consists of 30 items, and each item is rated on a 7-point scale, ranging from 1 (no symptoms) to 7 (extremely severe). |
| Primary | All-cause dropout rate | baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months | Marked by the treatment discontinuation for any reasons, including poor efficacy, intolerance of adverse reactions, poor compliance and other reasons. |
| Secondary | Change from baseline in Clinician-Rated Dimensions of Psychosis Symptom severity (CRDPS) | baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months | Clinician-Rated Dimensions of Psychosis Symptom severity (CRDPS). The CRDPS scale evaluates eight symptom dimensions of psychosis. Each symptom domain is rated for the past 7 days on a 5-point scale ranging from 0 (absent) to 4 (present and severe). |
| Secondary | Cost inventory | baseline,2 months,4 months, 6 months and 12 months | Direct medical costs (for example, antipsychotics costs, medical examinations costs, health care and service costs and adverse events costs) and indirect costs (such as traffic, nursing, and losing of labor) of the treatments. |
| Secondary | Change from baseline in Clinical Global Impression Scale-Severity (CGI-S) | baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months | Clinical Global Impression Scale-Severity (CGI-S), including assessment of disease severity and overall efficacy. The severity of the disease was scored on an eight-point scale ranging from 0 (not rated) to 7 (extremely severe). The overall efficacy was assessed on an 8-point scale ranging from 0 (not assessed) to 7 (significant deterioration). |
| Secondary | Change from baseline in Calgary Depression Scale for Schizophrenia (CDSS) | baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months | The Calgary Depression Scale for Schizophrenia (CDSS) consists of nine items, each scored from 0 to 3. A total score greater than 6 is considered depression. |
| Secondary | Social function | baseline,2 months,4 months and 6 months and 12 months | Chinese version of UPSA-B, the UCSD (University of California,San Diego) Performance-based Skills Assessment-Brief, consists of two parts: financial skill (A and B) and communication skill. The score of financial skill A range from 0 to 5. The score of financial skill B range from 0 to 6. The score of communication skill range from 0 to 9. The higher scores mean a better outcome. |
| Secondary | Life quality: The Heinirich Quality of life Scale (HRQOL) | baseline,2 months,4 months and 6 months and 12 months | The Heinirich Quality of life Scale (HRQOL) consists of 21 items, each scored from 0 to 6. The higher scores mean a better outcome. |
| Secondary | Life quality: Medication Satisfaction Questionnaire (MSN) | baseline,2 months,4 months and 6 months and 12 months | Medication Satisfaction Questionnaire (MSN) has one item, scored from 1 to 7. The higher scores indicate higher satisfaction with the medication. |
| Secondary | Life quality: Subjective Well-being under Neuroleptics (SWN) | baseline,2 months,4 months and 6 months and 12 months | Subjective Well-being under Neuroleptics (SWN) consists of 20 items, each scored from 1-6. |
1 to 10 of 38Source ClinicalTrials.gov
See all 38 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Paced Visual Serial Addition Test | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03510325
GET https://conductscience.org/api/trials/v1/NCT03510325/registered?page=2